Glp1

Medicare's Landmark Pilot: Weight-Loss Drugs Now Covered for Heart Health

Medicare Takes a Landmark Step: Pilot Program to Cover Weight-Loss Drugs for Heart Patients

Medicare's Landmark Shift: Finally Covering Ozempic-Style Drugs for Cardiovascular Health

The Next Frontier: How Pharma is Redefining GLP-1 Success Beyond the Pill

Pharma’s New Playbook: Merging Nutrition with GLP‑1 Therapy

Do GLP‑1 Medications Raise Testosterone? What the Science Actually Shows

The Unexpected Side Effect of Weight Loss: Understanding 'Ghost Fat'

Novo Nordisk Shares Rise After UK Greenlights First Daily GLP‑1 Weight‑Loss Pill, Healing Breach‑Related Wounds

The Weight of Progress: Employers Grapple with GLP-1 Costs and Coverage

The Weight of Wellness: How GLP-1 Costs Are Reshaping Employer Healthcare

Boehringer Ingelheim’s Survodutide Shows Strong Weight‑Loss Results in Late‑Stage Trial

The Road Ahead for Semaglutide Generics: Why API Capacity Is the Real Game‑Changer, Says Goldman Sachs

Mayim Bialik's GLP-1 Ordeal: A Candid Look at Severe Side Effects After One Shot

A New Chapter for Weight Loss: WW Leans into GLP-1s as Eli Lilly Explores Wider Medical Miracles

Medicare’s $50 GLP‑1 Weight‑Loss Plan: What the Numbers Really Mean

Medicare’s $50 Weight‑Loss Drug Plan: What the Numbers Really Mean

Can Wegovy Really Shift New Zealand’s Obesity Landscape?

The Protein Industrial Complex Is Here—And Fiber Is Knocking on the Door

The Weight Loss Revolution: Eli Lilly Unveils a New Horizon

Navigating the Hype: Are Popular Weight Loss Medications Right for *You*?

The RFK Jr. Effect: How a Presidential Candidate's Peptides Push Sent Hims & Hers Stock Soaring

The Weight Loss Revolution: Novo Nordisk's CEO Declares We've Only Just Begun

A New Dawn for Weight Loss? FDA Greenlights Game-Changing Oral GLP-1 Pill!

The Alarming Rise: GLP-1 Drugs Misused for Cosmetic Weight Loss in India

Imagine a Future: One Tiny Implant, Multiple Treatments for HIV, Obesity, and More

The Heart of the Matter: Do GLP-1 Medications Offer Lasting Protection, Or Is It A Momentary Truce?

GLP-1 Medications: The Unveiling Truth About Sustaining Heart Health Benefits

A Closer Look at GLP-1s: New Research Flags Potential Link to Sudden Sight Loss and 'Eye Stroke'

A New Chapter in Obesity Care: Novo Nordisk and Hims & Hers Team Up for Broader Access

Navigating the Untamed Frontier: Why the GLP-1 Market Still Feels Like the Wild West

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Quiet Revolution: Ozempic, the Brain, and the End of 'Food Noise'

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

GLP-1 Medications: Separating Hype from Health with Expert Insights

Navigating the New Frontier of Weight Loss: Scrutiny Mounts on Telehealth Providers

A Tale of Two Pivots: Hims & Hers Retreats on Weight-Loss Pill, Washington Post Sees Editorial Shift

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

Dr. Joel Habener, Visionary Pioneer of Diabetes Treatment and GLP-1 Research, Dies at 88

The Rebound Effect: What Happens When You Stop Taking Popular Weight-Loss Medications?